Sep 2026· Journal of Clinical Medicine· Vol 15, pp. 7266· 0 citations· 52 references
Medicine
TL;DR
The preclinical basis and emerging clinical evidence for lithium as a potential adjunct to radiotherapy while discussing key unresolved issues, including optimal timing, treatment duration, tumor safety, and patient selection are summarized.
Abstract
Central nervous system (CNS) tumors account for nearly one third of pediatric cancers and remain the leading cause of cancer-related mortality in children. Cranial radiotherapy is a cornerstone of treatment for many high-grade and embryonal brain tumors, often in combination with surgery and chemotherapy. However, improved survival has been accompanied by a growing burden of late neurocognitive, emotional, social, and endocrine sequelae. Damage to hippocampal neural stem and progenitor cells partly drives radiation-induced cognitive decline, which leads to reduced neurogenesis and increased gliogenesis. Lithium has emerged as a promising strategy to protect or repair the irradiated brain through its neuroprotective, anti-inflammatory, anti-apoptotic, and pro-neurogenic effects. Preclinical evidence supports its potential to mitigate radiation-induced brain injury. In cellular models, lithium appears to protect neural progenitors and hippocampal neurons from irradiation-related damage but does not confer comparable protection to tumor cells. In juvenile rodent models, lithium administration before, during, or after cranial irradiation has been associated with reduced apoptosis in hippocampal neurogenic regions, preservation or restoration of neurogenesis, attenuation of neuroinflammation, and improvement of cognitive and behavioral outcomes. Importantly, delayed lithium treatment has also shown restorative effects, indicating a potential role as a neuroregenerative strategy for survivors with late effects. Mechanistically, these benefits appear to arise from modulation of apoptotic pathways, GSK-3β-related signaling, neurogenic cell fate, and epigenetic programs that promote neuronal differentiation over gliogenesis. These data have provided the rationale for early clinical translation and ongoing trials now assessing whether lithium can improve neurocognitive outcomes after cranial radiotherapy in pediatric brain tumor patients. This narrative review summarizes the preclinical basis and emerging clinical evidence for lithium as a potential adjunct to radiotherapy while discussing key unresolved issues, including optimal timing, treatment duration, tumor safety, and patient selection.
PURPOSE OF REVIEW
Improved survival in primary CNS lymphoma (PCNSL) has increased the importance of delayed treatment-related neurotoxicity as a determinant of functional outcome and quality of life. This review summarizes contemporary evidence on neurocognitive outcomes across modern therapies and discusses the challe...
Angel Escamilla-Ramírez, C. Houillier, K. Hoang-Xuan· Current Opinion in Oncology· 0 citations
Human cortical organoids recapitulate key features of radiation-induced neural injury, recovery, and therapeutic modulation, providing a robust, scalable, and human-relevant platform for studying CNS radiation biology and preclinical screening of candidate radiation mitigators.
Ling He, H. Kornblum, A. Bhaduri et al.· Stem Cells Translational Med...· 0 citations
Pediatric brain tumors remain a leading cause of cancer-related mortality in children, partially due to ineffective delivery of systemic therapies across the blood-brain barrier (BBB). Unlike adults, the pediatric blood–brain barrier (BBB) in infants undergoes significant postnatal maturation during the first year of l...
Rapamycin, a potent mTORC1 inhibitor, is a leading candidate for treating age-related neurodegenerative disease. Numerous studies demonstrate beneficial effects in a variety of diseases that affect the brain. Yet a persistent belief among researchers is that rapamycin cannot penetrate brain tissue, citing as evidence i...
Jeffrey M. Melin, Nancy A. Young, Joseph Camardo· Journal of Alzheimer's Disea...· 0 citations
Using transcriptomic and proteomic approaches, ixazomib effectively triggers proteostatic stress responses and induces apoptosis across a histologic range of CNS malignancies and is effective against Myc-MB, ATRT and DMG tumors in vitro.
Elizabeth Janko, Faye Walker, Mathew Slade et al.· bioRxiv· 0 citations
Cancer-related cognitive impairment (CRCI) is often attributed to chemotherapy, yet cognitive deficits are detectable in some patients before systemic treatment begins. This review examines a proposed two-hit framework in which cancer-related psychological and physiological stress contributes to pretreatment neural vul...
Lijo Andrews, Yasmin El Khaldi, Tracy George et al.· Brain Science· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.